Lifesci Capital Has Strong Forecast for DYN FY2025 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Investment analysts at Lifesci Capital increased their FY2025 earnings per share (EPS) estimates for Dyne Therapeutics in a note issued to investors on Wednesday, January 21st. Lifesci Capital analyst F. Brisebois now expects that the company will post earnings per share of ($3.53) for the year, up from their prior estimate of ($3.58). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. Lifesci Capital also issued estimates for Dyne Therapeutics’ Q4 2025 earnings at ($0.81) EPS, Q1 2026 earnings at ($0.77) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.85) EPS and FY2026 earnings at ($3.24) EPS.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.05.

A number of other brokerages also recently issued reports on DYN. HC Wainwright boosted their price target on Dyne Therapeutics from $46.00 to $60.00 and gave the company a “buy” rating in a report on Monday, December 8th. Morgan Stanley increased their price objective on shares of Dyne Therapeutics from $46.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, December 8th. Sanford C. Bernstein set a $23.00 price target on Dyne Therapeutics in a report on Tuesday, December 9th. TD Cowen reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, December 8th. Finally, Wall Street Zen lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 28th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.41.

Dyne Therapeutics Stock Down 0.4%

Shares of NASDAQ DYN opened at $18.00 on Friday. The company has a 50-day moving average price of $19.38 and a 200-day moving average price of $15.77. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.47 and a quick ratio of 13.47. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $25.00. The stock has a market capitalization of $2.57 billion, a P/E ratio of -4.92 and a beta of 1.32.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at approximately $30,000. CWM LLC lifted its position in Dyne Therapeutics by 168.1% during the second quarter. CWM LLC now owns 3,030 shares of the company’s stock valued at $29,000 after purchasing an additional 1,900 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after buying an additional 1,109 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after buying an additional 955 shares in the last quarter. Finally, Arkadios Wealth Advisors bought a new stake in shares of Dyne Therapeutics in the 3rd quarter worth about $128,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics News Roundup

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised multiple quarterly and full‑year EPS forecasts and reiterated a “Strong‑Buy” rating, trimming FY2026 loss forecasts (improved EPS trajectory). This reduces modeled downside and supports valuation assumptions for a clinical‑stage biotech. Lifesci Capital raises estimates
• Positive Sentiment: Coverage/flow update — ClearBridge’s small‑cap growth fund added DYN in Q4, which can provide incremental buying pressure and credibility from a well‑known active manager. That can help near‑term liquidity and investor interest. ClearBridge small-cap growth trims Duolingo, Biohaven, QLYS; adds PTGX, SSD, BETA, DYN in Q4
• Positive Sentiment: Japan regulatory development: analysis on a recent Japanese orphan designation (or related nod) highlights potential market expansion and a clearer pathway for rare‑disease programs — a meaningful long‑term commercial and partnership positive if confirmed. How Does Japan’s Orphan Nod Shape Dyne Therapeutics’ (DYN) Global Rare-Disease Strategy?
• Negative Sentiment: JPMorgan reportedly lowered its expectations for DYN’s stock price — a negative signal that can weigh on sentiment and prompt short‑term selling or reduced conviction among some institutional holders. JPMorgan Chase & Co. Has Lowered Expectations for Dyne Therapeutics (NASDAQ:DYN) Stock Price

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.